HUE050756T2 - Arilalkilamin vegyületek rák megelõzésében vagy kezelésében történõ alkalmazásra - Google Patents
Arilalkilamin vegyületek rák megelõzésében vagy kezelésében történõ alkalmazásraInfo
- Publication number
- HUE050756T2 HUE050756T2 HUE15825825A HUE15825825A HUE050756T2 HU E050756 T2 HUE050756 T2 HU E050756T2 HU E15825825 A HUE15825825 A HU E15825825A HU E15825825 A HUE15825825 A HU E15825825A HU E050756 T2 HUE050756 T2 HU E050756T2
- Authority
- HU
- Hungary
- Prior art keywords
- cancer
- prevention
- treatment
- arylalkylamine compounds
- arylalkylamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196623 | 2014-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE050756T2 true HUE050756T2 (hu) | 2021-01-28 |
Family
ID=52015934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15825825A HUE050756T2 (hu) | 2014-12-05 | 2015-12-07 | Arilalkilamin vegyületek rák megelõzésében vagy kezelésében történõ alkalmazásra |
| HUE15825824A HUE049786T2 (hu) | 2014-12-05 | 2015-12-07 | Arilalkilamin vegyületek rák megelõzésében vagy kezelésében történõ alkalmazásra |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15825824A HUE049786T2 (hu) | 2014-12-05 | 2015-12-07 | Arilalkilamin vegyületek rák megelõzésében vagy kezelésében történõ alkalmazásra |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10258598B2 (hu) |
| EP (2) | EP3226852B1 (hu) |
| JP (2) | JP6875278B2 (hu) |
| CN (2) | CN107205965B (hu) |
| CA (2) | CA2968806A1 (hu) |
| HU (2) | HUE050756T2 (hu) |
| IL (2) | IL252493B (hu) |
| RU (2) | RU2731102C2 (hu) |
| WO (2) | WO2016088111A1 (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10258598B2 (en) | 2014-12-05 | 2019-04-16 | Semmelweis University | Compounds for use in the prevention or treatment of cancer |
| US11717575B2 (en) | 2019-05-20 | 2023-08-08 | Mabplex International Co., Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2035749A1 (hu) | 1969-02-06 | 1970-12-24 | Bellon Labor Sa Roger | |
| FR2536749A1 (fr) | 1982-11-25 | 1984-06-01 | Cerm Cent Europ Rech Mauvernay | (amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique |
| ATE65084T1 (de) | 1986-06-26 | 1991-07-15 | Ciba Geigy Ag | Hydrierte 1-benzooxacycloalkylpyridincarbons|ureverbindungen. |
| HU207280B (en) | 1986-09-25 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them |
| US5783606A (en) * | 1995-02-10 | 1998-07-21 | The University Of Toronto Innovations Foundation | Deprenyl compounds for treatment of glaucoma |
| JP2917189B2 (ja) | 1992-09-21 | 1999-07-12 | 株式会社間組 | ブロック製造用型枠及びブロックの製造法 |
| JPH09247445A (ja) | 1996-03-05 | 1997-09-19 | Ricoh Co Ltd | 画像読取装置 |
| KR100572900B1 (ko) | 1997-08-07 | 2006-04-24 | 후지모토 쿄다이 가부시키가이샤 | 에틸아민 유도체 |
| DE69902748T2 (de) * | 1998-01-13 | 2003-08-07 | Univ Saskatchewan | Propargylamin enthaltende zusammensetzung zur verbesserung der krebstherapie |
| JP4499208B2 (ja) | 1998-10-29 | 2010-07-07 | 株式会社フジモト・コーポレーション | 新規な光学活性アミノペンタン誘導体 |
| JP4953040B2 (ja) | 2001-09-19 | 2012-06-13 | 株式会社フジモト・コーポレーション | アポトーシス抑制剤 |
| JP4953041B2 (ja) | 2001-09-19 | 2012-06-13 | 株式会社フジモト・コーポレーション | アポトーシス抑制剤 |
| US20040266808A1 (en) * | 2003-06-27 | 2004-12-30 | Kamen Barton A. | Treatment of antifolate neurotoxicity |
| JP5030194B2 (ja) | 2004-11-25 | 2012-09-19 | 国立大学法人九州大学 | 薬物依存症治療剤 |
| GB2451495A (en) * | 2007-08-01 | 2009-02-04 | Inion Ltd | Treatment of inflammation by modulating catecholamine metabolism |
| RU2453309C1 (ru) * | 2011-05-11 | 2012-06-20 | Государственное образовательное учреждение высшего профессионального образования Пущинский государственный университет | Средство, обладающее цитотоксической активностью по отношению к раковым клеткам человека в культуре |
| CN103826625A (zh) * | 2011-07-26 | 2014-05-28 | 南加州大学 | 单胺氧化酶抑制剂及前列腺癌的治疗和诊断方法 |
| WO2013063492A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| US10258598B2 (en) | 2014-12-05 | 2019-04-16 | Semmelweis University | Compounds for use in the prevention or treatment of cancer |
-
2015
- 2015-12-07 US US15/533,067 patent/US10258598B2/en active Active
- 2015-12-07 CA CA2968806A patent/CA2968806A1/en not_active Abandoned
- 2015-12-07 RU RU2017122192A patent/RU2731102C2/ru active
- 2015-12-07 CN CN201580066294.0A patent/CN107205965B/zh active Active
- 2015-12-07 EP EP15825825.1A patent/EP3226852B1/en active Active
- 2015-12-07 WO PCT/IB2015/059405 patent/WO2016088111A1/en active Application Filing
- 2015-12-07 HU HUE15825825A patent/HUE050756T2/hu unknown
- 2015-12-07 US US15/533,091 patent/US10258599B2/en active Active
- 2015-12-07 JP JP2017529749A patent/JP6875278B2/ja active Active
- 2015-12-07 CN CN201580066295.5A patent/CN107205966B/zh active Active
- 2015-12-07 JP JP2017529752A patent/JP6875279B2/ja active Active
- 2015-12-07 EP EP15825824.4A patent/EP3226851B1/en active Active
- 2015-12-07 HU HUE15825824A patent/HUE049786T2/hu unknown
- 2015-12-07 RU RU2017122205A patent/RU2714893C2/ru active
- 2015-12-07 CA CA2968793A patent/CA2968793C/en active Active
- 2015-12-07 WO PCT/IB2015/059407 patent/WO2016088112A1/en active Application Filing
-
2017
- 2017-05-24 IL IL252493A patent/IL252493B/en active IP Right Grant
- 2017-05-24 IL IL252487A patent/IL252487B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017122205A (ru) | 2019-01-11 |
| RU2017122205A3 (hu) | 2019-07-17 |
| CN107205965A (zh) | 2017-09-26 |
| JP2018505851A (ja) | 2018-03-01 |
| JP2018505852A (ja) | 2018-03-01 |
| US10258599B2 (en) | 2019-04-16 |
| IL252487A0 (en) | 2017-07-31 |
| US10258598B2 (en) | 2019-04-16 |
| IL252487B (en) | 2019-12-31 |
| WO2016088112A1 (en) | 2016-06-09 |
| CN107205965B (zh) | 2020-10-27 |
| EP3226852B1 (en) | 2020-03-18 |
| RU2731102C2 (ru) | 2020-08-28 |
| US20170319535A1 (en) | 2017-11-09 |
| EP3226851B1 (en) | 2020-03-18 |
| IL252493A0 (en) | 2017-07-31 |
| JP6875279B2 (ja) | 2021-05-19 |
| WO2016088111A1 (en) | 2016-06-09 |
| CA2968793A1 (en) | 2016-06-09 |
| RU2017122192A (ru) | 2019-01-09 |
| EP3226852A1 (en) | 2017-10-11 |
| CN107205966A (zh) | 2017-09-26 |
| RU2017122192A3 (hu) | 2019-06-20 |
| RU2714893C2 (ru) | 2020-02-20 |
| CA2968806A1 (en) | 2016-06-09 |
| CA2968793C (en) | 2022-02-08 |
| JP6875278B2 (ja) | 2021-05-19 |
| CN107205966B (zh) | 2021-01-26 |
| IL252493B (en) | 2020-04-30 |
| US20170340582A1 (en) | 2017-11-30 |
| EP3226851A1 (en) | 2017-10-11 |
| HUE049786T2 (hu) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247202A1 (zh) | 用於治療癌症的化合物 | |
| IL249065A0 (en) | Combination of treatments for cancer treatment | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| LT3122358T (lt) | Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui | |
| IL259996A (en) | Combinations for cancer treatment | |
| IL251905B (en) | Epilimod for use in the treatment of kidney cancer | |
| IL248767B (en) | Trimethoxyphenyl-benzaimidazole compounds for cancer treatment | |
| IL251371A0 (en) | Cortexolone 17alpha-benzoate for use in the treatment of tumors | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| HK1231561A1 (zh) | 癌症治療 | |
| IL251903A0 (en) | Epilimod for use in the treatment of colon cancer | |
| EP3440052C0 (en) | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| IL252487A0 (en) | Arylalkylamine compounds for use in the prevention or treatment of cancer | |
| HK1217430A1 (zh) | 表面處理劑 | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| ZA201403006B (en) | Composition for use in treatment of cancer | |
| EP3125903A4 (en) | Method for use of homopiperazinium compounds in the treatment of cancer | |
| GB201410695D0 (en) | Uses of oligouronates in cancer treatment |